Clinical Trials Logo

Hepatobiliary Neoplasm clinical trials

View clinical trials related to Hepatobiliary Neoplasm.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT06049836 Completed - Clinical trials for Hepatobiliary Neoplasm

Holographic Augmented Reality Versus Screen Visualisation of 3D Rendering Models for the Pre-operative Evaluation and Planning of Liver Resections

Start date: October 15, 2023
Phase: N/A
Study type: Interventional

The goal of this trial is to compare the evaluation of 3D liver models visualised as holograms with HoloLens 2 and on digital PDF files in HPB surgical trainees. The main questions it aims to answer are: - Do the holographic models allow a superior accuracy in terms of anatomical evaluation and surgical planning? - Is there any difference in terms of time consumed and Task Load Index? Participants will analyse cases through both modalities and answer a questionnaire.

NCT ID: NCT04959630 Completed - Clinical trials for Hepatobiliary Neoplasm

Immersive Virtual Reality Environment for Complex Cognitive Skills Curricular Training in Liver Surgery

LiVeRTrainer
Start date: September 1, 2020
Phase: N/A
Study type: Interventional

Investigators hypothesize that a virtual reality (VR) environment enhances general surgery residents' performance compared to Desktop Interface (DI)-based visualization of 3D models in decision making for patients with liver tumors. To determine this, a proficiency-based stepwise training curriculum for preoperative planning has been developed using both modalities. The overall objective of the curriculum is that by the end of the training program, residents would be able to formulate a treatment plan for patients with liver tumors.

NCT ID: NCT04642664 Completed - Cholangiocarcinoma Clinical Trials

Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer

ACABC
Start date: December 1, 2018
Phase: Phase 2
Study type: Interventional

The investigators design a prospective clinical study to explore the efficacy and safety of apatinib plus camrelizumab in pretreated patients with advanced biliary tract malignant tumors and to analyze potential biomarkers of therapeutic response.

NCT ID: NCT01135849 Completed - Breast Cancer Clinical Trials

B-Receptor Signaling in Cardiomyopathy

Start date: November 2008
Phase: N/A
Study type: Observational

We hope to determine the importance of different genes (including B receptors) in anthracycline-induced cardiomyopathy. This has important benefits to patients exposed to anthracyclines, as this could help determine whether certain individuals have increased susceptibility to cardiac injury.